Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals completed the Phase 1b study of its lead INTASYL compound PH-762 and has submitted a meeting request and comprehensive briefing package to the FDA supporting a planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. The briefing package describes the nonclinical development program, integrated clinical pharmacology data, and the completed Phase 1b results, along with the scientific rationale, study design, and pharmacokinetic strategy for the next stage.
Key figures
- Drug Name
- PH-762
- Phase Of Trial
- Phase 1b completed; Phase 2b neoadjuvant proposed
- Indication
- cutaneous squamous cell carcinoma
- Nct number
- NCT# 06014086
- Toxicology dosing phase
- completed
- Clinical supplies available
- Q1 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.